Efficacy News and Research

RSS
Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

PHT announces availability of NetPRO eClinical solution for public

PHT announces availability of NetPRO eClinical solution for public

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Interventional radiologists complete RDN human trial in patients with uncontrolled hypertension

Interventional radiologists complete RDN human trial in patients with uncontrolled hypertension

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

International Phase II trial to study LY2181308 efficacy in patients with lung cancer

International Phase II trial to study LY2181308 efficacy in patients with lung cancer

Cleveland Medical Devices Inc. spins off Great Lakes NeuroTech

Cleveland Medical Devices Inc. spins off Great Lakes NeuroTech

PHOENIX phase III trial of PHP for distributive shock to continue after positive midpoint recommendation from DMB

PHOENIX phase III trial of PHP for distributive shock to continue after positive midpoint recommendation from DMB

Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes

Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes

GE Healthcare launches Centricity Research, a new clinical research management solution

GE Healthcare launches Centricity Research, a new clinical research management solution

Cancer drug Gleevec may hold promise against scleroderma: Study

Cancer drug Gleevec may hold promise against scleroderma: Study

A.P. Pharma fourth quarter revenue decreases to $1.6 million

A.P. Pharma fourth quarter revenue decreases to $1.6 million

BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients

Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients

Tengion 2010 adjusted net loss decreases to $25.8 million

Tengion 2010 adjusted net loss decreases to $25.8 million

Emory plays key role in bringing advanced proton cancer therapy to Georgia

Emory plays key role in bringing advanced proton cancer therapy to Georgia

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.